



LJMU Research Online

Webb, RJ, Lodge, JK, Scott, SS and Davies, IG

Metabolomic Characterisation of Low-Density Lipoproteins Isolated from Iodixanol and KBr-Based Density Gradient Ultracentrifugation

<http://researchonline.ljmu.ac.uk/id/eprint/25386/>

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Webb, RJ, Lodge, JK, Scott, SS and Davies, IG (2025) Metabolomic Characterisation of Low-Density Lipoproteins Isolated from Iodixanol and KBr-Based Density Gradient Ultracentrifugation. *Metabolites*, 15 (2).

LJMU has developed **LJMU Research Online** for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk

<http://researchonline.ljmu.ac.uk/>

Article

Metabolomic Characterisation of Low-Density Lipoproteins Isolated from Iodixanol and KBr-Based Density Gradient Ultracentrifugation

Richard J. Webb ¹ , John K. Lodge ^{2,3} , Sophie S. Scott ³ and Ian G. Davies ^{4,*} ¹ School of Health and Sport Sciences, Liverpool Hope University, Liverpool L16 9JD, UK² School of Human Sciences, London Metropolitan University, London N7 8DB, UK³ Department of Applied Sciences, Northumbria University, Newcastle-Upon-Tyne NE1 7ST, UK⁴ Research Institute of Sport and Exercise Sciences, Faculty of Science, Liverpool John Moores University, Liverpool L3 3AF, UK

* Correspondence: i.g.davies@ljmu.ac.uk; Tel.: +44-151-231-5290

Abstract: Background/Objectives: Salt-based density gradient ultracentrifugation (SBUC) is frequently used to isolate lipoproteins for their subsequent analysis. However, the addition of salts may disrupt their molecular composition. Therefore, the aim of the present study was to assess the impact of SBUC upon the molecular composition of low-density lipoprotein (LDL) particles, compared to a validated non-salt method involving iodixanol gradient ultracentrifugation (IGUC). Methods: Whole human plasma was analysed for various lipid parameters before LDL particles were isolated using both SBUC and IGUC methods. Each fraction was then filtered to obtain low-molecular-weight compounds. The LDL molecular content of the resulting fractions from both methods was determined using untargeted liquid chromatography–mass spectrometry (LC-MS) in positive and negative modes. Results: A total of 1041 and 401 features were putatively identified using positive and negative modes, respectively. Differences were shown in the molecular composition of LDL prepared using SBUC and IGUC; in positive mode ionisation, the PLS-DA model showed reasonable fit and discriminatory power ($R^2 = 0.63$, $Q^2 = 0.58$, accuracy 0.88) and permutation testing was significant ($p < 0.001$). Conclusions: The findings reveal distinct differences in the small molecule composition of LDL prepared using the two methods, with IGUC exhibiting greater variation. In negative mode, both methods detected phospholipids, long-chain sphingolipids, and ceramides, but IGUC showed higher fold differences for some phospholipids. However, in positive mode, non-native brominated adducts were found in LDL isolated using SBUC and evidence of potential bacterial contamination was discovered in samples prepared using IGUC, both of which have the capacity to affect in vitro experiments.

Keywords: lipoprotein; KBr; iodixanol; LC-MS; LDL; ultracentrifugation; metabolomics



Academic Editor: Bei Gao

Received: 13 December 2024

Revised: 12 January 2025

Accepted: 14 January 2025

Published: 22 January 2025

Citation: Webb, R.J.; Lodge, J.K.; Scott, S.S.; Davies, I.G. Metabolomic Characterisation of Low-Density Lipoproteins Isolated from Iodixanol and KBr-Based Density Gradient Ultracentrifugation. *Metabolites* **2025**, *15*, 68. <https://doi.org/10.3390/metabo15020068>

Copyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Lipoproteins are a diverse species of particles and are a rich source of polar and non-polar molecules [1–3]. Advances in metabolomic techniques allow for the analysis of a plethora of molecules with biological processes above and beyond traditional lipid metabolism [1,4]. Small non-polar and amphipathic molecules found within the interior and phospholipid surface monolayer of lipoprotein particles have garnered attention in recent years due to their wide-ranging functions. Using salt-based gradient ultracentrifugation (SBUC), various phospholipids and sphingolipids across different lipoproteins in

different populations have been detected [5–7], showing involvement in various metabolic pathways, highlighting their potential diversity and metabolic importance. For example, higher levels of sphingolipids and ceramides with lower levels of phosphatidylcholines, located on the surface of LDL, increased the susceptibility of LDL aggregation [8]. This is a key step in the pathogenesis of atherosclerotic cardiovascular disease, which is modifiable with dietary intervention, both negatively with, e.g., saturated fat [8], and positively with *n*-3 fatty acids [9]. Furthermore, differences in the severity of carotid lesions have recently been shown to be dependent on the LDL lipidome [10]. Furthermore, HDL isolated from patients with chronic kidney disease containing saturated and monounsaturated phosphatidylcholines, ceramides, and sphingomyelins with long-chain fatty acids was associated with increased all-cause mortality [11]. Similarly, HDL particles separated using SBUC from patients who had experienced an acute ST-segment elevation myocardial infarction were associated with increased proinflammatory lysolipids and alterations to intermediate-to-long-chain unsaturated phospholipid and sphingolipid species [12]. Conversely, a decrease in proinflammatory proteins was found in HDL isolated using SBUC from a single patient with severe COVID-19 who was administered with recombinant HDL, highlighting the potential utility of these insights to inform clinical practice [13].

The majority of lipidomic studies concerned with lipoproteins have focused on small non-polar molecules associated with the interior or the phospholipid surface monolayer [1,5]. To the authors' knowledge, only one study has investigated additional small polar molecules (SPMs) attracted to, and non-covalently bonded to, the negative electrostatic charge on the lipoprotein surface [2]. This study analysed the VLDL, IDL, and LDL classes and HDL subclasses separated using SBUC showing several diverse SPMs, such as fatty acids, lactic acid, glucose, pentitol, and gulonic acid, attached to the surface of the HDL subfractions. Many of these were shown to correlate with insulin resistance, waist circumference, and glycolytic pathways, highlighting the far-reaching influence of these lipoprotein-associated molecules.

SBUC remains the most used lipoprotein separation method, likely due to its ubiquity in laboratories and well-defined, easily implemented SBUC protocols. SBUC requires the addition of either NaBr or KBr [14–17], offering a preparative separation for a wide range of analyses (e.g., traditional lipids, apolipoproteins, and 'omics'). However, its ionic nature generates a hyperosmotic environment surrounding the lipoproteins, which induces a loss of water, increases their density, and disrupts the associated apolipoproteins [18], potentially leading to the dissolution of small polar molecules (SPMs). In addition, the increased centrifugation times (for some methods) can lead to a loss of associated proteins and alterations of the lipid components rendering LDL more susceptible to oxidation, and increased exposure to shear forces can dissociate apolipoproteins [19,20]. The use of D₂O has been proposed as an alternative density gradient medium, with the composition of VLDL and LDL fractions being identical to those separated using KBr [21], and this method has been recently used with success to compare the molecular composition of LDL against the liver lipidome, revealing positive relationships with dihydroceramides and ceramides [22]. Furthermore, Ståhlman et al. [23] compared ionic KBr and a non-ionic combination of sucrose/D₂O and found that sucrose/D₂O yielded higher total protein and apolipoprotein levels in both HDL and LDL. Despite this, sucrose's hygroscopic nature could affect lipoprotein hydration, making it less ideal for SPM analysis, and D₂O may be prohibitively costly for some applications. We previously developed a method of separating LDL using a non-ionic density gradient medium, iodixanol gradient ultracentrifugation (IGUC) [24]. Iodixanol is inert, non-toxic, non-osmotic, and non-hygroscopic [25], and it separates LDL with a lower density [24,26], which is suggestive of maintaining a native

hydration status. Furthermore, IGUC times are often shorter than those outlined in SBUC methods, which reduces exposure to shear forces.

Currently, there is a dearth of research investigating small molecules in the light of different density gradient media for lipoprotein ultracentrifugation. We aimed to address this by comparing a commonly used method of lipoprotein separation using potassium bromide (KBr) ultracentrifugation [17] with our previously validated method using iodixanol [24], which we hypothesised to be less disruptive to the small molecule composition of low-density lipoprotein (LDL). We hypothesise a unique ‘lipoprotein-omic’ approach using a superior non-ionic ultracentrifugation method combined with liquid chromatography–mass spectrometry (LC-MS) to investigate the presence and identity of these molecules in lipoproteins with a greater degree of sensitivity and, therefore, increase the potential for biomarker discovery.

2. Materials and Methods

2.1. Reagents

Optiprep (iodixanol), KBr, and Amicon ultra-centrifugal filters with a 30 Da cut-off were purchased from Sigma (St. Louis, MO, USA). For the analysis of plasma and lipoprotein classes, total cholesterol, triglycerides, HDL-C, small dense LDL (sdLDL), and apolipoprotein B (apoB) kits were purchased from Randox Laboratories Ltd. (Crumlin, UK). Optiseal™ (11.2 mL) ultracentrifuge tubes were purchased from Beckman-Coulter (Brea, CA, USA).

2.2. Participant Recruitment

Healthy male volunteers ($n = 21$) were recruited from Liverpool John Moores University (LJMU) via emails and posters, as well as verbally.

2.3. Inclusion/Exclusion Criteria

All potential participants completed a screening questionnaire prior to consenting. Any potential participants who were using lipid-lowering medication or who had taken part in any other study over the previous 3 months which may have influenced their lipid profile were excluded from the study. Smokers were also excluded, as were participants using electronic implants, e.g., cardiac pacemakers, active prostheses, electronic life-support systems, e.g., artificial hearts, artificial lungs, or portable electronic medical devices, e.g., ECGs.

2.4. Ethical Approval

Ethical approval was granted by LJMU research ethics committee (REC Number: 16/ELS/012) following the principles of the Declaration of Helsinki for the use of human participants. Informed consent was obtained from all subjects involved in the study.

2.5. Participant Characteristics

Participants were characterised by age, body mass, and BMI using standard anthropometric methods. Body composition (body fat percentage, fat-free mass, etc.) was analysed using a SECA MBca 515 bioimpedance scale (SECA, Hamburg, Germany). Plasma samples were analysed for total cholesterol, triglycerides, apoB, sdLDL, and HDL-C using a Randox Daytona autoanalyser (Randox, Crumlin, UK).

2.6. Collection and Preparation of Plasma and Ultracentrifugation Methods

A blood sample was drawn from each participants’ antecubital vein using an EDTA-coated vacutainer tube. Plasma was then separated from the blood using low-speed centrifugation as described previously [24]. Plasma was separated into LDL and its sub-

classes using iodixanol and potassium bromide (KBr) lipoprotein separation methods. The methods of Davies et al. [24] and Chung et al. [17] were employed to separate LDL using IGUC and an adapted KBr SBUC, respectively. Both methods involved centrifugation for 3 h at 341,000 $g_{(av)}$ in a Beckman Coulter Optima XPN-80 ultracentrifuge and a Beckman Coulter NVT-65 rotor (Beckman Coulter, Brea, CA, USA) with acceleration programme 5 and deceleration programme 5.

2.7. Fractionation and Determination of LDL

The resulting samples from both methods were fractionated using a Labconco Auto 147 Densi-Flow 115V (Labconco, Kansas City, MO, USA) and a Gilson FC203B fraction collector (Gilson Inc., Middleton, WI, USA) to generate 20 fractions of ~500 μL [17]. A proportion (circa 20 μL) of each fraction was analysed for its refractive index using an Abbe refractometer (Bellingham and Stanley, Basingstoke, UK). The refractive indices were converted to density using the following formula: $\rho = \eta a - b$. Here, $a = 3.2984$, $b = 3.3967$, η = refractive index, and ρ = density [24]. For standard characterisation a small portion (circa 180 μL) of whole plasma and gradient fractions were analysed for cholesterol using a Randox Daytona autoanalyser (Randox, Crumlin, UK). LDL was determined using previously described cutoffs [17,24].

2.8. Preparation of Isolated LDL Samples

LDL samples were filtered through molecular weight centrifugal filters (30 Da) as per the manufacturer's instructions. Each sample was centrifuged for 30 min at 10 degrees, and the resulting filtrate was then used for metabolomic analysis. Briefly, 50 μL of the filtrate was taken and mixed with an equivolume of chilled methanol (LC-MS pure), mixed and centrifuged (10,000 rpm) to remove any pellet, and then the supernatant was transferred to a sample vial for analysis.

2.9. Metabolomic Analysis of LDL Samples

Hydrophilic interaction liquid chromatography (HILIC)-based analysis was conducted using ultra high-resolution liquid chromatography (UHPLC) and mass spectrometry (MS) [27]. Metabolite profiles were generated on a Dionex 3000 ultra high-pressure liquid chromatography (UHPLC) system hyphenated to a Q-Exactive classic high-resolution mass spectrometer system (ThermoScientific, Bremen, Germany). All solvents and ionisation agents used were of analytical grade or higher unless stated. The chromatographic separation was performed on a Water Acuity Ethylene Bridge Hybrid Amide analytical column (2.1 \times 150 mm) with a particle size of 1.7 micron at a flow rate of 400 $\mu\text{L}/\text{min}$; the column temperature was set to 45 $^{\circ}\text{C}$. The binary buffer system was as follows: Buffer A was MilliQ water and Buffer B was acetonitrile, both with 10 mM ammonium formate adjusted to pH 3.5 using formic acid.

The LC profile was as follows: T:0 min: 90% (B); T:2 min 60% (B); T:5 min 40% (B); T:7.5 min 40% (B); T:7.6 min 90% (B); T:10 min 90% (B). A 3 μL injection was applied. The heated spray ionisation source (HESI) was set to the following parameters: a sheath gas flow rate of 50, an aux gas flow rate of 13, and a sweep gas flow rate of 3. The spray voltage was set to 3.5 kV with a Capillary temperature of 275 $^{\circ}\text{C}$. The aux gas heater temperature was adjusted to 425 $^{\circ}\text{C}$. The mass (MS1) acquisition range was as follows: 75–1000 m/z units at a mass resolution of 35,000 at approximately 7.6 scans per second, a microscan of 1, and the lock mass off. The AGC was set to 1×10^6 and the ion injection time was 100 mS^{-1} . The data were acquired on both positive and negative mode polarity (independently); the setting for the negative mode was the same as that for positive ion mode except the voltage was set to 2.5 kV. The system was primed with a minimum of 10 sequential injections of pooled QC to stabilise the HESI and to check for chromatographic stability before initialling

the batch analysis. All samples were analysed with relevant QCs and in a randomised order to reduce any time effects of the analysis.

Peak table generation and alignment were performed using Compound Discoverer 2.1 (ThermoScientific, Bremen, Germany) with an alignment window of 0.25 min, a mass tolerance of 5 ppm, and a signal intensity threshold of 200,000 counts with a signal-to-noise ratio of 5:1.

2.10. Characterisation and Identification of Discriminating Features

Peak intensity tables from Compound Discoverer were processed using MetaboAnalyst© software, version 3 [28]. The full dataset was autoscaled. MetaboAnalyst performed detailed multivariate and univariate analyses, including Principal Component Analysis, which was used for data quality control, and Partial Least Squares Discriminant Analysis (PLS-DA), which was used to test for discrimination between sample groups. Cross-validation tests were used to test the robustness of the model, using Q2, R2, and classification metrics, while Variable Importance in Projection (VIP) data were used to rank the most discriminatory species. Annotation of the identified metabolites was carried out according to level 2 of the identification proposed by the Metabolomics Standards Initiative [29]. Firstly, the top discriminating features (VIP > 1.7, fold change > 0.19) in each mode underwent putative identification of these features, which was performed using the established database UCSD Metabolomics Workbench [30] and the Human metabolite database [31].

3. Results

3.1. Participant Characteristics

A total of 21 otherwise healthy males (mean age 39.0 years) participated in the study and had a mean BMI of 26.5 kg/m² and a waist circumference of 93.0 cm, as described in Table 1. Participants also had a mean average of 2.4 L of visceral adipose tissue. In terms of the standard lipid profile, all markers were in the normal range apart from total cholesterol, which was slightly elevated at 5.32 mmol/L. Apolipoprotein B was 72.81 mg/dL and sdLDL was 0.75 mmol/L. Finally, plasma glucose levels were 5.82 mmol/L and mean plasma protein was 76.03 g/L.

Table 1. Participant characteristics and metabolic markers.

Variable	Mean ± SD
Sex	All male
Age	39.0 ± 12.2
Height (m)	1.77 ± 0.1
Weight (kg)	82.5 ± 8.9
BMI (kg/m ²)	26.5 ± 3.0
Fat mass (kg)	20.3 ± 7.3
Fat mass (%)	24.2 ± 7.1
Fat-free mass (kg)	62.2 ± 5.7
Fat-free mass (%)	75.7 ± 7.2
Visceral adipose tissue (L)	2.4 ± 1.1
Waist circumference (cm)	93.0 ± 10.0
Triglycerides (mmol/L)	1.07 ± 0.47
Total cholesterol (mmol/L)	5.32 ± 1.20
LDL-C (mmol/L)	3.00 ± 1.05
HDL-C (mmol/L)	1.36 ± 0.33
Apolipoprotein B (mg/dL)	72.81 ± 22.27
sdLDL (mmol/L)	0.75 ± 0.38
Glucose (mmol/L)	5.82 ± 0.61
Total protein (g/L)	76.03 ± 3.12

Abbreviations: BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; sdLDL, small dense LDL.

3.2. Metabolite Profiling

Samples containing LDL from both IGUC and SBUC fractionation were compared. The analysis identified 1041 and 401 features in positive and negative mode, respectively. Initially, PCA was used to identify any outlying samples, but none were found, so we proceeded to establish supervised models of discrimination between the fractionation methods. Figure 1 shows a PLS-DA score plot of a representative analysis of LDL comparing the fractionation methods, in positive mode ionisation. The model shows reasonable fit and discriminatory power ($R^2 = 0.63$, $Q^2 = 0.58$, accuracy 0.88). Permutation testing (1000 permutations) on prediction accuracy was significant ($p < 0.001$). Although samples from IGUC and SBUC fractions were clustered separately, those from iodixanol display a larger variation through component 2 and were separated into distinct clusters not seen in the SBUC fractions. All samples were within Hotelling's confidence band, even though certain samples appeared in the other cluster. A heat map of the top 100 discriminatory features (Figure 2) shows similar intensity profiles for each treatment class. The heat map also highlights that certain sample profiles are more representative of the opposite treatment. Similar results were found in negative mode.




Figure 1. PLS-DA score plot comparing the LDL fractionation methods, in positive mode ionisation.

Tables 2 and 3 show the top discriminatory species in each ionisation mode with a VIP either >2.0 (positive mode) or >1.7 (negative mode). To putatively identify discriminatory ions, closest matches were obtained from metabolite databases, and these preliminary identities are also shown in Tables 2 and 3. Therefore, metabolite identifications are level 2 of the Metabolomics Standards Initiative [29]. There is limited crossover of preliminary annotations between ionisation modes with no single species predominating. However, negative mode did highlight lipid species, such as analogues of PA and PE, whilst positive mode highlighted certain bromine adducts.




Figure 2. Heat map of top discriminatory features for each treatment class, in positive mode.

Table 2. Top discriminatory species, positive mode.

m/z	VIP (>2)	t.stat	p-Value	FDR	Highest In	Fold Change	Top Match (M + H, 15 ppm Tolerance)	Formula
425.81546	2.1308	-9.8971	5.28×10^{-15}	4.38×10^{-12}	salt	0.19	8-bromo-adenosine-5' monophosphate	$C_{10}H_{14}N_5O_7PBr$
124.05287	2.1207	9.7866	8.41×10^{-15}	4.38×10^{-12}	iodixanol	4.21	N-(2-Pyrimidinyl)formamide	$C_5H_5N_3O$
561.79088	2.0985	-9.5502	2.28×10^{-14}	6.70×10^{-12}	salt	0.19	No match	
1027.7386	2.0957	-9.5213	2.57×10^{-14}	6.70×10^{-12}	salt	0.28	PIP(PGF1alpha/18:0)	$C_{47}H_{88}O_{19}P_2$
581.85625	2.0815	-9.3765	4.75×10^{-14}	9.89×10^{-12}	salt	0.34	Nakamuric acid	$C_{20}H_{22}N_7O_4$
513.8688	2.0695	-9.2563	7.90×10^{-14}	1.24×10^{-11}	salt	0.27	2,5-Diaminopyrimidine nucleoside triphosphate	$C_9H_{19}N_5O_{14}P_3$
341.85409	2.0621	-9.1846	1.07×10^{-13}	1.24×10^{-11}	salt	0.19	Cyano-6,8-dibromo-4-methylcoumarin	$C_{11}H_6NO_2$
457.76313	2.0441	-9.0112	2.24×10^{-13}	2.33×10^{-11}	salt	0.25	Convolutamine A	$C_{13}H_{19}NO_2$
445.88095	2.0397	-8.9701	2.67×10^{-13}	2.52×10^{-11}	salt	0.26	6-Bromo-3,4-di(4'-chlorophenyl)coumarin	$C_{21}H_{12}O_{22}$
377.89385	2.0235	-8.8204	5.04×10^{-13}	4.04×10^{-11}	salt	0.24	(3S)-3-(2,3-Dibromo-4,5-dihydroxybenzyl)pyrroline	$C_{11}H_{10}NO_4$
525.75106	2.0147	-8.7399	7.11×10^{-13}	4.35×10^{-11}	salt	0.20	3,3'-Diiodothyronine	$C_{12}H_{14}NO_5$
289.84044	2.0109	-8.7058	8.22×10^{-13}	4.75×10^{-11}	salt	0.27	S-(4-Bromo-benzyl)cysteine	$C_{15}H_{14}NO_4$
651.75996	2.0095	-8.6932	8.67×10^{-13}	4.75×10^{-11}	salt	0.23	2S,3R-didecanoyl-docosane-2,3-diol	$C_{10}H_{13}O_2S$
325.87984	2.0062	-8.6646	9.80×10^{-13}	4.86×10^{-11}	salt	0.22	(4S)-2-Bromo-4-[(5R)-2-amino-4-oxo-2-imidazolin-5-yl]butanoic acid TG derivative	$C_{20}H_{17}O_5S$
375.79974	2.0013	-8.6204	1.18×10^{-12}	5.60×10^{-11}	salt	0.28	caelestine D	$C_{11}H_{13}N_5O_2$
593.73856	2	-8.6078	1.25×10^{-12}	5.65×10^{-11}	salt	0.19	Arachidyl arachidate	$C_{11}H_8NO_4$

Table 3. Top discriminatory species, negative mode.

<i>m/z</i>	VIP (>1.75)	t.stat	<i>p</i> -Value	FDR	Highest In	Fold Change	Top Match (M-H, 15 ppm Tolerance)	Formula
517.82311	1.8786	−12.559	8.14×10^{-20}	1.82×10^{-17}	salt	0.28	14-Oxo-aerophobin2	C ₁₆ H ₁₈ N ₅ O ₅
601.78459	1.8768	−12.522	9.44×10^{-20}	1.82×10^{-17}	salt	0.29	Guanosine 3',5'-bis(diphosphate)	C ₁₀ H ₁₆ N ₅ O ₁₇ P ₄
501.84957	1.869	−12.359	1.81×10^{-19}	1.82×10^{-17}	salt	0.26	Deltamethrin	C ₂₂ H ₁₈ NO ₃
585.8107	1.8689	−12.357	1.82×10^{-19}	1.82×10^{-17}	salt	0.27	Adenosine tetraphosphate	C ₁₀ H ₁₆ N ₅ O ₁₆ P ₄
533.79708	1.8586	−12.147	4.20×10^{-19}	2.81×10^{-17}	salt	0.33	Trimethylpentatriacontane	C ₃₈ H ₇₇
617.75814	1.8553	−12.082	5.47×10^{-19}	3.13×10^{-17}	salt	0.32	methyl tricosanyl oleate	C ₄₂ H ₈₁ O ₂
569.83678	1.8441	−11.865	1.31×10^{-18}	6.56×10^{-17}	salt	0.23	Iopanoic acidD	C ₁₁ H ₁₁ NO ₂
433.86207	1.8341	−11.678	2.79×10^{-18}	1.24×10^{-16}	salt	0.29	Oxyclozanide	C ₁₉ H ₁₆ NO ₅ S ₃
349.90199	1.8083	−11.221	1.81×10^{-17}	5.59×10^{-16}	salt	0.29	alpha-D-glucuronate 1-phosphate(Br adduct)	C ₁₀ H ₁₀ NO ₃
365.87555	1.8048	−11.161	2.32×10^{-17}	6.64×10^{-16}	salt	0.35	-(1,3-Benzoxazol-2-YL)-2,6-di-bromophenol	C ₁₃ H ₆ NO ₂
551.76936	1.7917	−10.944	5.69×10^{-17}	1.52×10^{-15}	salt	0.27	keronopsin A2	C ₁₈ H ₁₃ NO ₆ S
719.6917	1.7898	−10.913	6.45×10^{-17}	1.62×10^{-15}	salt	0.23	hydroxyphthioceranic acid (C48)	C ₄₈ H ₉₅ O ₃
657.88869	1.787	10.868	7.78×10^{-17}	1.84×10^{-15}	iodixanol	5.30	No match	
856.85394	1.7828	10.802	1.02×10^{-16}	2.28×10^{-15}	iodixanol	11.74	PE/CerP	C ₅₁ H ₁₀₃ NO ₆ P
1723.7027	1.7752	10.682	1.69×10^{-16}	3.56×10^{-15}	iodixanol	7.52	Microspinosamide	C ₇₅ H ₁₀₈ N ₁₈ O ₂₂ S
1315.7779	1.7646	10.52	3.32×10^{-16}	6.65×10^{-15}	iodixanol	5.22	PA derivative	C ₆₈ H ₁₁₁ N ₆ O ₁₉
801.65486	1.7613	−10.469	4.11×10^{-16}	7.48×10^{-15}	salt	0.24	PA/PE/PG derivative	C ₄₆ H ₉₀ O ₈ P
589.90225	1.7514	10.323	7.58×10^{-16}	1.22×10^{-14}	iodixanol	4.67	UDP-2-acetamido-2,6-dideoxy-beta-L-talose	C ₁₇ H ₂₆ N ₃ O ₁₆ P ₂
1587.7285	1.7513	10.321	7.63×10^{-16}	1.22×10^{-14}	iodixanol	6.79	No match	

4. Discussion

The primary aim of this study was to develop and apply a novel ‘lipoprotein-omic’ approach to investigate lipoprotein metabolite composition, comparing IGUC and SBUC by employing LC-MS. We hypothesised that IGUC would maintain native hydration status in LDL separation while challenging the commonly used SBUC LDL density method. We show here that LDL isolated from the two treatments have very different metabolite profiles.

We found that LDL samples fractionated using IGUC exhibited greater variation along component 2 and were separated into distinct clusters. This clustering pattern was not observed in the samples fractionated by salt, indicating a difference in the two methods, although it should be noted that the origin of the molecules is unknown. The intensity profiles of the samples were generally consistent within each treatment class (Figure 2), but certain samples displayed characteristics more representative of the opposite treatment, highlighting some overlap between the fractionation methods.

This overlap was shown when using negative ion mode, as both UC methods identified a range of phospholipids on the surface of LDL particles, e.g., PE and PA, that contribute to the structural integrity, fluidity, lipid transfer, and molecular interactions of LDL [32]. We also found lipid species consistent with long-chain sphingolipids or ceramides, known for enhancing LDL stability, supporting membrane structure, and participating in cellular signalling, with potential roles in modulating inflammatory and aggregation responses [8]. Other studies have also shown the presence of these phospholipids in LDL particles, emphasising their importance in identifying cardiovascular disease risk above and beyond LDL-C [3,33]. Furthermore, it has also been shown that some molecules found on LDL, such as sphingolipids, are positively associated with corresponding species found in the liver lipidome, suggesting that molecular inter-relations may extend beyond LDL particles themselves [22].

We also putatively identified key discriminatory ions based on VIP and fold changes in ion intensities, which differed between treatment groups. These included phosphatidylethanolamines, the amino sugar UDP-2-acetamido-2,6-dideoxy-beta-L-talose, and peptides which were detected in the IGUC samples when using negative ion mode, and they were all found to have a fold change >4. The higher fold difference in some phospholipids (e.g., PE/CerP) observed with IGUC suggests that SBUC may facilitate the

dissociation of these lipids from LDL particles, potentially due to the disruptive effects of high salt concentrations on lipid–lipoprotein interactions. Similarly, in positive ion mode, N-(2-Pyrimidinyl)formamide was also found to be higher in the IGUC treatment group. Despite having rather low fold change values, several brominated adducts were also identified in the SBUC treatment group only. It is suspected that these compounds may have been formed during the separation process and result from interactions between KBr, which was added as a density gradient medium in supraphysiological concentrations, and molecules within plasma. These adducts are not native to LDL but need to be considered when preparing lipoproteins for subsequent *in vitro* experiments as they may potentially distort results. To the authors' knowledge there are no studies that have specifically investigated the impact of these molecules in LDL *in vitro* experiments. However, as studies investigating LDL typically address myriad research questions, such as cellular uptake, oxidation, glycation, aggregation, other modifications, and DNA alterations [8,33,34], they provide ample opportunities for brominated compounds to potentially interfere. This is supported by evidence from pharmaceutical research which has shown that brominated nucleotides have the ability to damage DNA [35]. There is little research to draw upon specifically regarding LDL, but we speculate that isolating these lipoproteins using SBUC may affect subsequent *in vitro* experiments, potentially distorting results. This is reflected in the evidence which does exist; for example, Canclini et al. compared an SBUC against IGUC, the precipitation of apoB containing lipoproteins and fast protein liquid chromatography, for separation of LDL and the subsequent analysis of proprotein convertase subtilisin/kexin type-9 (PCSK9) [36]. The findings revealed heterogeneity between methods, with PCSK9 appearing to be sensitive to SBUC but not IGUC, which may have direct consequences for future investigations aiming to further elucidate the function of PCSK9 as well broader potential implications for any experiments requiring the isolation of LDL using ultracentrifugation [36].

In contrast, the IGUC method, unsurprisingly, did not result in the formation of brominated adducts, preserving LDL in its native-like state. This is important, as phospholipids such as phosphatidylethanolamine and phosphatidic acid, along with sphingolipids and ceramides, are increasingly being recognised as biomarkers for cardiometabolic and cardiovascular disease [37,38]. Most studies, however, have focused on whole plasma/serum, with only a small number of studies utilising LDL. For example, a recent study investigated the impact of phosphor- and sphingolipids and, in the LDL particle, showed higher levels of certain phosphatidylethanolamines and sphingomyelins with more severe cases of carotid lesions [10]. Additionally, understanding the downstream effects of metabolic disease is vital for gaining further insights regarding atherosclerotic cardiovascular disease (ASCVD). In this respect, Lahelma et al. [22] showed that in patients with obesity that the liver and LDL lipidomes are correlated, reflecting hepatic lipid metabolism and its influence on LDL composition. This suggests that alterations in hepatic lipid metabolism due to obesity may directly contribute to the atherogenic potential of LDL particles, providing a mechanistic link between metabolic dysfunction and ASCVD progression. These studies highlight the importance of preserving the LDL lipidome as close to its native-like state, which therefore enhances the utility of the IGUC method in cardiometabolic research. In contrast, SBUC's potential disruption of these lipids could lead to the loss of valid information about LDL's role in disease pathways. Therefore, the choice of separation method may directly impact the reliability of the results.

However, IGUC does present its own concerns, with evidence of bacterial contamination. We found UDP-2-acetamido-2,6-dideoxy-beta-L-talose in negative mode with IGUC; this is a microbial lipopolysaccharide (LPS) by-product which may possibly suggest contamination during sample handling or potentially *in vivo* LPS translocation from the

gut into the blood where binding to LDL may have occurred. The potential detection of LPS on LDL, whether in vitro or in vivo, has possible implications since LPS binding can modify LDL's oxidative state and inflammatory properties [39,40], potentially influencing findings related to LDL's function in cardiovascular health and immune interactions. SBUC may be a better choice to avoid contamination, as the high salt gradient inhibits bacterial growth and reduces the risk of microbial by-products, making it more suitable for studies where LPS binding or bacterial contamination could affect results, particularly in inflammation or immune-related LDL research. On the other hand, this finding could also represent an opportunity to explore novel LDL–LPS interactions, particularly in the context of gut-derived inflammation and its connection to cardiovascular risk. In endotoxemia, LPS binds to lipoproteins, including LDL in the blood, and this interaction is influenced by its phospholipid content [41]. IGUC may offer a more accurate platform for studying these interactions by preserving the native PL composition of LDL, enabling better insights into lipoprotein–LPS interactions.

Further research is required to confirm the presence of novel metabolites located on LDL, including the source of bacterial contamination. To further improve the accuracy of experiments using IGUC, implementing stricter sterile handling protocols, filtering plasma samples before ultracentrifugation, using antimicrobial treatments, and performing quality control checks for contamination before and after separation to minimise bacterial presence are recommended.

Other common consistencies found in the IGUC samples were that identified compounds generally had higher fold changes and greater molecular weights, particularly in negative mode. That said, whilst we appreciate that the metabolite assignments are putative (level 2 of the Metabolomics Standards Initiative), there did not appear to be any additional patterns in the class of metabolites predominating in either treatment. Furthermore, the overlap in the discriminatory ions between positive and negative ionisation modes was limited, with no single species dominating across both.

5. Limitations

There are several limitations with our study that should be acknowledged. The sample size was small and homogeneous, with only 21 healthy male participants. While we provide valuable insights, the lack of diversity limits the generalisability of the findings to broader populations, including females and individuals with different health conditions or lipid profiles. Future studies should include larger and more representative cohorts to validate these results and assess their relevance across a wider range of populations, including those with cardiovascular diseases or other metabolic disorders.

Both ultracentrifugation methods used in the study present inherent limitations. While IGUC appears to preserve LDL in a more native-like state, the risk of bacterial contamination remains a concern. On the other hand, SBUC avoids contamination but results in the formation of non-native brominated compounds that may be disruptive regarding in vitro experimental work. These methodological trade-offs suggest that neither method is without shortcomings, and further optimisation of LDL separation techniques is needed to ensure more accurate and reliable results. It should also be noted that environmental attributes, including temperature and pressure, have previously been shown to affect the visibility of plasma lipids, lipoproteins, and their subclasses after isolation via ultracentrifugation and analysis using nuclear magnetic resonance spectroscopy [42]. Attributes such as these were not robustly accounted for in the present study and should be considered for future investigations.

The study also relied on the putative identification of metabolites based on established databases and followed level 2 of the Metabolomics Standards Initiative. While these

findings provide valuable initial insights, they remain tentative. Confirmatory studies using more targeted approaches, such as tandem mass spectrometry (MS/MS) or isotopically labelled standards, are required to validate the identity of the metabolites and confirm their physiological relevance.

Additionally, the robustness of the study's findings could be strengthened through more extensive cross-validation. While cross-validation tests were used to evaluate the PLS-DA model, further validation using larger and more diverse datasets would enhance confidence in the results and improve their applicability to broader populations.

6. Conclusions

Both UC methods putatively identified a range of phospholipids and long-chain sphingolipids/ceramides on the surface of LDL, highlighting the utility of these methods for investigating LDL's role in cardiovascular disease risk beyond LDL-C. However, both methods have limitations, with SBUC uniquely leading to the formation of brominated adducts, which are not native to LDL. In contrast, IGUC preserved LDL in a more native-like state with higher fold differences for some phospholipids but presented challenges with potential bacterial contamination. Both methods could impact in vitro experiments by altering LDL's interactions. While further work is needed to confirm our findings, we recommend using sterile protocols and quality control to ensure the accuracy and reliability of LDL preparation.

Author Contributions: Conceptualization, I.G.D., R.J.W. and J.K.L.; methodology, I.G.D., R.J.W. and J.K.L.; software, J.K.L. and S.S.S.; validation, J.K.L. and S.S.S.; formal analysis, J.K.L. and S.S.S.; investigation, R.J.W. and I.G.D.; resources, I.G.D. and J.K.L.; data curation, J.K.L., R.J.W. and S.S.S.; writing—original draft preparation, R.J.W., I.G.D. and J.K.L.; writing—review and editing, all authors; visualisation, J.K.L.; supervision, I.G.D. and J.K.L.; project administration, I.G.D.; funding acquisition, I.G.D., J.K.L. and R.J.W. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Leverhulme Trust Project Grant, grant number RPG-2016-114.

Institutional Review Board Statement: This study was conducted in accordance with the Declaration of Helsinki and approved by the Research Ethics Committee (REC) of Liverpool John Moores University (REC Number: 16/ELS/012).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.

Conflicts of Interest: The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. Kontush, A.; Chapman, M.J. Lipidomics as a tool for the study of lipoprotein metabolism. *Curr. Atheroscler. Rep.* **2010**, *12*, 194–201. [[CrossRef](#)] [[PubMed](#)]
2. Hyotylainen, T.; Mattila, I.; Wiedmer, S.K.; Koivuniemi, A.; Taskinen, M.R.; Yki-Jarvinen, H.; Oresic, M. Metabolomic analysis of polar metabolites in lipoprotein fractions identifies lipoprotein-specific metabolic profiles and their association with insulin resistance. *Mol. Biosyst.* **2012**, *8*, 2559–2565. [[CrossRef](#)] [[PubMed](#)]
3. Chapman, M.J.; Orsoni, A.; Tan, R.; Mellett, N.A.; Nguyen, A.; Robillard, P.; Giral, P.; Thérond, P.; Meikle, P.J. LDL subclass lipidomics in atherogenic dyslipidemia: Effect of statin therapy on bioactive lipids and dense LDL. *J. Lipid Res.* **2020**, *61*, 911–932. [[CrossRef](#)]
4. Zhang, B.; Schmidlin, T. Recent advances in cardiovascular disease research driven by metabolomics technologies in the context of systems biology. *npj Metab. Health Dis.* **2024**, *2*, 25. [[CrossRef](#)]

5. Serna, J.; Garcia-Seisdedos, D.; Alcazar, A.; Lasuncion, M.A.; Busto, R.; Pastor, O. Quantitative lipidomic analysis of plasma and plasma lipoproteins using MALDI-TOF mass spectrometry. *Chem. Phys. Lipids* **2015**, *189*, 7–18. [[CrossRef](#)]
6. Reis, A.; Rudnitskaya, A.; Blackburn, G.J.; Mohd Fauzi, N.; Pitt, A.R.; Spickett, C.M. A comparison of five lipid extraction solvent systems for lipidomic studies of human LDL. *J. Lipid Res.* **2013**, *54*, 1812–1824. [[CrossRef](#)]
7. Rauschert, S.; Gázquez, A.; Uhl, O.; Kirchberg, F.F.; Demmelair, H.; Ruíz-Palacios, M.; Prieto-Sánchez, M.T.; Blanco-Carnero, J.E.; Nieto, A.; Larqué, E.; et al. Phospholipids in lipoproteins: Compositional differences across VLDL, LDL, and HDL in pregnant women. *Lipids Health Dis.* **2019**, *18*, 20. [[CrossRef](#)]
8. Ruuth, M.; Nguyen, S.D.; Vihervaara, T.; Hilvo, M.; Laajala, T.D.; Kondadi, P.K.; Gisterå, A.; Lähteenmäki, H.; Kittilä, T.; Huusko, J.; et al. Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths. *Eur. Heart J.* **2018**, *39*, 2562–2573. [[CrossRef](#)]
9. Erkkilä, A.T.; Manninen, S.; Fredrikson, L.; Bhalke, M.; Holopainen, M.; Ruuth, M.; Lankinen, M.; Käkälä, R.; Öörni, K.; Schwab, U.S. Lipidomic changes of LDL after consumption of Camelina sativa oil, fatty fish and lean fish in subjects with impaired glucose metabolism—A randomized controlled trial. *J. Clin. Lipidol.* **2021**, *15*, 743–751. [[CrossRef](#)]
10. Nieddu, G.; Michelucci, E.; Formato, M.; Ciampelli, C.; Obino, G.; Signore, G.; Di Giorgi, N.; Rocchiccioli, S.; Lepedda, A.J. Molecular Characterization of Plasma HDL, LDL, and VLDL Lipids Cargos from Atherosclerotic Patients with Advanced Carotid Lesions: A Preliminary Report. *Int. J. Mol. Sci.* **2022**, *23*, 12449. [[CrossRef](#)]
11. Lidgard, B.; Hoofnagle, A.N.; Zelnick, L.R.; de Boer, I.H.; Fretts, A.M.; Kestenbaum, B.R.; Lemaitre, R.N.; Robinson-Cohen, C.; Bansal, N. High-Density Lipoprotein Lipidomics and Mortality in CKD. *Kidney Med.* **2023**, *5*, 100708. [[CrossRef](#)] [[PubMed](#)]
12. Ponnaiah, M.; Zakiev, E.; Lhomme, M.; Rached, F.; Camont, L.; Serrano, C.V., Jr.; Santos, R.D.; Chapman, M.J.; Orekhov, A.; Kontush, A. Acute myocardial infarction preferentially alters low-abundant, long-chain unsaturated phospholipid and sphingolipid species in plasma high-density lipoprotein subpopulations. *Atheroscler. Plus* **2024**, *55*, 21–30. [[CrossRef](#)] [[PubMed](#)]
13. Tanaka, S.; Begue, F.; Veeren, B.; Tran-Dinh, A.; Robert, T.; Tashk, P.; Lortat-Jacob, B.; Faille, D.; de Chaisemartin, L.; Zappella, N.; et al. First Recombinant High-Density Lipoprotein Particles Administration in a Severe ICU COVID-19 Patient, a Multi-Omics Exploratory Investigation. *Biomedicines* **2022**, *10*, 754. [[CrossRef](#)] [[PubMed](#)]
14. Griffin, B.A.; Caslake, M.J.; Yip, B.; Tait, G.W.; Packard, C.J.; Shepherd, J. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. *Atherosclerosis* **1990**, *83*, 59–67. [[CrossRef](#)]
15. Groot, P.H.; Scheek, L.M.; Havekes, L.; van Noort, W.L.; van't Hooft, F.M. A one-step separation of human serum high density lipoproteins 2 and 3 by rate-zonal density gradient ultracentrifugation in a swinging bucket rotor. *J. Lipid Res.* **1982**, *23*, 1342–1353. [[CrossRef](#)]
16. Chung, B.H.; Segrest, J.P.; Cone, J.T.; Pfau, J.; Geer, J.C.; Duncan, L.A. High resolution plasma lipoprotein cholesterol profiles by a rapid, high volume semi-automated method. *J. Lipid Res.* **1981**, *22*, 1003–1014. [[CrossRef](#)]
17. Chung, B.H.; Segrest, J.P.; Ray, M.J.; Brunzell, J.D.; Hokanson, J.E.; Krauss, R.M.; Beaudrie, K.; Cone, J.T. [8] *Single Vertical Spin Density Gradient Ultracentrifugation*; Elsevier: Amsterdam, The Netherlands, 1986; Volume 128, pp. 181–209.
18. Murdoch, S.J.; Breckenridge, W.C. Development of a Density Gradient Ultracentrifugation Technique for the Resolution of Plasma-Lipoproteins Which Avoids Apo-E Dissociation. *Anal. Biochem.* **1994**, *222*, 427–434. [[CrossRef](#)]
19. Carbonneau, M.A.; Cartron, E.; Leger, C.L.; Senglat, C.; Descomps, B. New insight on the relationship between LDL composition, associated proteins, oxidative resistance and preparation procedure. *Free Radic. Res.* **2002**, *36*, 127–142. [[CrossRef](#)]
20. van't Hooft, F.; Havel, R.J. Metabolism of apolipoprotein E in plasma high density lipoproteins from normal and cholesterol-fed rats. *J. Biol. Chem.* **1982**, *257*, 10996–11001. [[CrossRef](#)]
21. Hallberg, C.; Hådén, M.; Bergström, M.; Hanson, G.; Pettersson, K.; Westerlund, C.; Bondjers, G.; Ostlund-Lindqvist, A.M.; Camejo, G. Lipoprotein fractionation in deuterium oxide gradients: A procedure for evaluation of antioxidant binding and susceptibility to oxidation. *J. Lipid Res.* **1994**, *35*, 1–9. [[CrossRef](#)]
22. Lahelma, M.; Qadri, S.; Ahlholm, N.; Porthan, K.; Ruuth, M.; Juuti, A.; Orešič, M.; Hyötyläinen, T.; Öörni, K.; Yki-Järvinen, H. The human liver lipidome is significantly related to the lipid composition and aggregation susceptibility of low-density lipoprotein (LDL) particles. *Atherosclerosis* **2022**, *363*, 22–29. [[CrossRef](#)] [[PubMed](#)]
23. Stahlman, M.; Davidsson, P.; Kanmert, I.; Rosengren, B.; Boren, J.; Fagerberg, B.; Camejo, G. Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. *J. Lipid Res.* **2008**, *49*, 481–490. [[CrossRef](#)] [[PubMed](#)]
24. Davies, I.G.; Graham, J.M.; Griffin, B.A. Rapid separation of LDL subclasses by iodixanol gradient ultracentrifugation. *Clin. Chem.* **2003**, *49*, 1865–1872. [[CrossRef](#)] [[PubMed](#)]
25. Ford, T.; Graham, J.; Rickwood, D. Iodixanol: A nonionic iso-osmotic centrifugation medium for the formation of self-generated gradients. *Anal. Biochem.* **1994**, *220*, 360–366. [[CrossRef](#)] [[PubMed](#)]
26. Graham, J.M.; Griffin, B.A.; Davies, I.G.; Higgins, J.A. Fractionation of lipoprotein subclasses in self-generated gradients of iodixanol. *Methods Mol. Med.* **2001**, *52*, 51–59. [[CrossRef](#)]
27. Langer, S.; Kennel, A.; Lodge, J.K. The influence of juicing on the appearance of blueberry metabolites 2 h after consumption: A metabolite profiling approach. *Br. J. Nutr.* **2018**, *119*, 1233–1244. [[CrossRef](#)]

28. Xia, J.; Wishart, D.S. Using MetaboAnalyst 3.0 for comprehensive metabolomics data analysis. *Curr. Protoc. Bioinform.* **2016**, *55*, 14.10.11–14.10.91. [[CrossRef](#)]
29. Sumner, L.W.; Amberg, A.; Barrett, D.; Beale, M.H.; Beger, R.; Daykin, C.A.; Fan, T.W.-M.; Fiehn, O.; Goodacre, R.; Griffin, J.L. Proposed minimum reporting standards for chemical analysis. *Metabolomics* **2007**, *3*, 211–221. [[CrossRef](#)]
30. UCSD. The Metabolomics Workbench. Available online: <https://www.metabolomicsworkbench.org/> (accessed on 28 February 2023).
31. Wishart, D.S.; Feunang, Y.D.; Marcu, A.; Guo, A.C.; Liang, K.; Vázquez-Fresno, R.; Sajed, T.; Johnson, D.; Li, C.; Karu, N. HMDB 4.0: The human metabolome database for 2018. *Nucleic Acids Res.* **2017**, *46*, D608–D617. [[CrossRef](#)]
32. Hevonoja, T.; Pentikäinen, M.O.; Hyvönen, M.T.; Kovanen, P.T.; Ala-Korpela, M. Structure of low density lipoprotein (LDL) particles: Basis for understanding molecular changes in modified LDL. *Biochim. Biophys. Acta (BBA)—Mol. Cell Biol. Lipids* **2000**, *1488*, 189–210. [[CrossRef](#)]
33. Ding, M.; Rexrode, K.M. A Review of Lipidomics of Cardiovascular Disease Highlights the Importance of Isolating Lipoproteins. *Metabolites* **2020**, *10*, 163. [[CrossRef](#)] [[PubMed](#)]
34. Liu, Y.X.; Liu, X.W.; Yang, Y.J.; Li, S.H.; Bai, L.X.; Ge, W.B.; Xu, X.; Li, C.; Li, J.Y.; Qin, Z. AEE alleviates ox-LDL-induced lipid accumulation and inflammation in macrophages. *Biomed. Pharmacother.* **2023**, *167*, 115486. [[CrossRef](#)] [[PubMed](#)]
35. Park, Y.; Polska, K.; Rak, J.; Wagner, J.R.; Sanche, L. Fundamental mechanisms of DNA radiosensitization: Damage induced by low-energy electrons in brominated oligonucleotide trimers. *J. Phys. Chem. B* **2012**, *116*, 9676–9682. [[CrossRef](#)] [[PubMed](#)]
36. Canclini, L.; Malvandi, A.M.; Uboldi, P.; Jabnati, N.; Grigore, L.; Zambon, A.; Baragetti, A.; Catapano, A.L. The Association of Proprotein Convertase Subtilisin/Kexin Type 9 to Plasma Low-Density Lipoproteins: An Evaluation of Different Methods. *Metabolites* **2021**, *11*, 861. [[CrossRef](#)]
37. Foran, D.; Antoniadis, C.; Akoumianakis, I. Emerging Roles for Sphingolipids in Cardiometabolic Disease: A Rational Therapeutic Target? *Nutrients* **2024**, *16*, 3296. [[CrossRef](#)]
38. Qian, X.; Jia, H.; Wang, J.; He, S.; Yu, M.; Feng, X.; Gong, Q.; An, Y.; Wang, X.; Shi, N.; et al. Circulating palmitoyl sphingomyelin levels predict the 10-year increased risk of cardiovascular disease death in Chinese adults: Findings from the Da Qing Diabetes Study. *Cardiovasc. Diabetol.* **2024**, *23*, 37. [[CrossRef](#)]
39. Memon, R.A.; Stapsans, I.; Noor, M.; Holleran, W.M.; Uchida, Y.; Moser, A.H.; Feingold, K.R.; Grunfeld, C. Infection and inflammation induce LDL oxidation in vivo. *Arterioscler. Thromb. Vasc. Biol.* **2000**, *20*, 1536–1542. [[CrossRef](#)]
40. Wang, H.; Reddy, S.T.; Fogelman, A.M. The role of gut-derived oxidized lipids and bacterial lipopolysaccharide in systemic inflammation and atherosclerosis. *Curr. Opin. Lipidol.* **2022**, *33*, 277–282. [[CrossRef](#)]
41. Kumar, P.; Schroder, E.A.; Rajaram, M.V.S.; Harris, E.N.; Ganesan, L.P. The Battle of LPS Clearance in Host Defense vs. Inflammatory Signaling. *Cells* **2024**, *13*, 1590. [[CrossRef](#)]
42. Baumstark, D.; Kremer, W.; Boettcher, A.; Schreier, C.; Sander, P.; Schmitz, G.; Kirchhoefer, R.; Huber, F.; Kalbitzer, H.R. (1)H NMR spectroscopy quantifies visibility of lipoproteins, subclasses, and lipids at varied temperatures and pressures. *J. Lipid Res.* **2019**, *60*, 1516–1534. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.